RxDoctor Payments Data

Joseph Vanvaler, MD

Neurology · Muncie, INNPI 1689629180

Payments from drug & device makers

$17,847in general payments, 2019–2025

Across 402 payments — averaging $44.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$8K
  • Acadia Pharmaceuticals Inc$997
  • Livanova USA, Inc.$887
  • Sanofi$804
  • AbbVie$795
  • Neurocrine Biosciences, Inc.$671
  • plus $6K from 39 others

What the payments were for

  • Speaking & faculty fees$7,25041%
  • Food & beverage$10,59759%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,847 in reported general payments places this provider in the 70th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$101,937
Medicare patients
447
Services billed
1,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab20$171,348
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5018$149,179
AptiomEslicarbazepine Acetate18$36,602
UbrelvyUbrogepant15$30,374
XcopriCenobamate21$25,442
RytaryCarbidopa/Levodopa15$19,201
BriviactBrivaracetam12$17,340
Levetiracetam274$10,949
Lacosamide52$7,933
Pyridostigmine Bromide39$7,060
Memantine Hcl216$6,473
Carbidopa-Levodopa ErCarbidopa/Levodopa106$6,432
DilantinPhenytoin Sodium Extended12$5,892
Carbidopa-LevodopaCarbidopa/Levodopa187$4,734
Ropinirole Hcl105$3,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$277$36,60218 claims
AbbVieUbrelvy$795$30,37415 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$37$26,26154 claims
SK Life Science, Inc.Xcopri$21$25,44221 claims
UCB, Inc.Briviact$299$17,34012 claims
PfizerDilantin$108$5,89212 claims
Upsher-smith Laboratories LLCTopiramate$13$2,124128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 308 neurology providers in Indiana.

Other neurology in Muncie

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →